Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Abnormal cerebrospinal fluid (CSF) dynamics in Alzheimer's disease and normal pressure hydrocephalus: CSF-amyloid β precursor protein metabolites as possible biomarkers.

Lahiri DK, Ray B.

Eur J Neurol. 2013 Feb;20(2):211-3. doi: 10.1111/j.1468-1331.2012.03832.x. Epub 2012 Aug 31. No abstract available.

PMID:
22934632
2.

Soluble amyloid precursor protein α in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus.

Miyajima M, Nakajima M, Ogino I, Miyata H, Motoi Y, Arai H.

Eur J Neurol. 2013 Feb;20(2):236-42. doi: 10.1111/j.1468-1331.2012.03781.x. Epub 2012 Jun 4.

PMID:
22672777
3.

Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus.

Jeppsson A, Höltta M, Zetterberg H, Blennow K, Wikkelsø C, Tullberg M.

Fluids Barriers CNS. 2016 Jul 29;13(1):13. doi: 10.1186/s12987-016-0037-y.

4.

Idiopathic normal-pressure hydrocephalus, cerebrospinal fluid biomarkers, and the cerebrospinal fluid tap test.

Kang K, Ko PW, Jin M, Suk K, Lee HW.

J Clin Neurosci. 2014 Aug;21(8):1398-403. doi: 10.1016/j.jocn.2013.11.039. Epub 2014 May 14.

PMID:
24836892
5.

Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers.

Jeppsson A, Zetterberg H, Blennow K, Wikkelsø C.

Neurology. 2013 Apr 9;80(15):1385-92. doi: 10.1212/WNL.0b013e31828c2fda. Epub 2013 Mar 13.

PMID:
23486875
6.

Ventricular and lumbar cerebrospinal fluid concentrations of Alzheimer's disease biomarkers in patients with normal pressure hydrocephalus and posttraumatic hydrocephalus.

Brandner S, Thaler C, Lelental N, Buchfelder M, Kleindienst A, Maler JM, Kornhuber J, Lewczuk P.

J Alzheimers Dis. 2014;41(4):1057-62. doi: 10.3233/JAD-132708.

PMID:
24748118
7.

Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.

Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, Kararizou E, Vassilopoulos D.

Eur J Neurol. 2007 Feb;14(2):168-73.

PMID:
17250725
8.

Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus.

Graff-Radford NR.

Neurology. 2014 Oct 21;83(17):1573-5. doi: 10.1212/WNL.0000000000000916.

9.

CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.

Agren-Wilsson A, Lekman A, Sjöberg W, Rosengren L, Blennow K, Bergenheim AT, Malm J.

Acta Neurol Scand. 2007 Nov;116(5):333-9.

PMID:
17922727
10.

Tau protein is a potential biological marker for normal pressure hydrocephalus.

Kudo T, Mima T, Hashimoto R, Nakao K, Morihara T, Tanimukai H, Tsujio I, Koike Y, Tagami S, Mori H, Nakamura Y, Tanaka T, Mori K, Takeda M.

Psychiatry Clin Neurosci. 2000 Apr;54(2):199-202.

11.

Low cerebrospinal-fluid concentrations of soluble amyloid beta-protein precursor in hereditary Alzheimer's disease.

Farlow M, Ghetti B, Benson MD, Farrow JS, van Nostrand WE, Wagner SL.

Lancet. 1992 Aug 22;340(8817):453-4.

PMID:
1354785
12.

Analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics.

Li X, Miyajima M, Mineki R, Taka H, Murayama K, Arai H.

Acta Neurochir (Wien). 2006 Aug;148(8):859-64; discussion 864. Epub 2006 Jun 6.

PMID:
16755327
13.

A new sandwich immunoassay for detection of the α-secretase cleaved, soluble amyloid-β protein precursor in cerebrospinal fluid and serum.

Taverna M, Straub T, Hampel H, Rujescu D, Lichtenthaler SF.

J Alzheimers Dis. 2013;37(4):667-78. doi: 10.3233/JAD-130509.

PMID:
23948916
15.

Decreased levels of soluble amyloid beta-protein precursor are associated with Alzheimer's disease in concordant and discordant monozygous twin pairs.

Wagner SL, Peskind ER, Nochlin D, Provow S, Farrow JS, Pandian MR, Cleveland M, Ito RK, Farlow MR.

Ann Neurol. 1994 Aug;36(2):215-20.

PMID:
8053657
16.

Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.

Hock C, Golombowski S, Müller-Spahn F, Naser W, Beyreuther K, Mönning U, Schenk D, Vigo-Pelfrey C, Bush AM, Moir R, Tanzi RE, Growdon JH, Nitsch RM.

Eur Neurol. 1998;39(2):111-8.

PMID:
9520072
17.

Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease.

Nakamura T, Shoji M, Harigaya Y, Watanabe M, Hosoda K, Cheung TT, Shaffer LM, Golde TE, Younkin LH, Younkin SG, et al.

Ann Neurol. 1994 Dec;36(6):903-11.

PMID:
7998778
18.

Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.

Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus Ch, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kölsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J.

Mol Psychiatry. 2010 Feb;15(2):138-45. doi: 10.1038/mp.2008.84. Epub 2008 Jul 29.

PMID:
18663368
19.

Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients.

Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E.

Neurosci Lett. 2000 Jan 14;278(3):169-72.

PMID:
10653020

Supplemental Content

Support Center